JPMorgan Chase & Co. Grows Stock Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

JPMorgan Chase & Co. raised its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 342.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,068,796 shares of the company's stock after acquiring an additional 1,601,477 shares during the period. JPMorgan Chase & Co. owned approximately 5.66% of iTeos Therapeutics worth $15,888,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. State Street Corp grew its stake in shares of iTeos Therapeutics by 21.9% during the third quarter. State Street Corp now owns 1,175,353 shares of the company's stock worth $12,000,000 after buying an additional 211,452 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in iTeos Therapeutics by 3.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 222,135 shares of the company's stock worth $2,268,000 after buying an additional 8,397 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of iTeos Therapeutics by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 640,350 shares of the company's stock valued at $6,540,000 after purchasing an additional 20,092 shares during the period. Empowered Funds LLC boosted its holdings in shares of iTeos Therapeutics by 5.0% during the 4th quarter. Empowered Funds LLC now owns 69,072 shares of the company's stock worth $530,000 after buying an additional 3,305 shares in the last quarter. Finally, Virtu Financial LLC boosted its stake in iTeos Therapeutics by 84.3% during the fourth quarter. Virtu Financial LLC now owns 18,493 shares of the company's stock worth $142,000 after acquiring an additional 8,460 shares in the last quarter. Institutional investors own 97.16% of the company's stock.

Wall Street Analysts Forecast Growth

ITOS has been the subject of several recent research reports. Wedbush restated an "outperform" rating and set a $25.00 price objective on shares of iTeos Therapeutics in a report on Wednesday, March 5th. Wells Fargo & Company dropped their target price on shares of iTeos Therapeutics from $19.00 to $17.00 and set an "overweight" rating on the stock in a research report on Thursday, March 6th. HC Wainwright reissued a "buy" rating and issued a $46.00 price target on shares of iTeos Therapeutics in a report on Thursday, March 6th. Finally, JPMorgan Chase & Co. reduced their price objective on iTeos Therapeutics from $22.00 to $15.00 and set an "overweight" rating for the company in a report on Thursday, March 6th.

iTeos Therapeutics Price Performance

NASDAQ:ITOS traded down $0.20 during trading hours on Thursday, hitting $6.02. The stock had a trading volume of 65,092 shares, compared to its average volume of 467,626. iTeos Therapeutics, Inc. has a one year low of $4.80 and a one year high of $18.75. The company has a 50 day simple moving average of $6.63 and a two-hundred day simple moving average of $7.76. The firm has a market capitalization of $229.89 million, a price-to-earnings ratio of -1.91 and a beta of 1.43.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last announced its earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.13. Equities research analysts anticipate that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.